[Recent advances in pathophysiology, diagnosis and treatment of steroid-refractory graft-versus-host disease].

Acute graft-versus-host disease (GVHD) is a major life-threating complication that occurs after allogeneic cell transplantation. Although steroids remain the first-line treatment, approximately one-third of patients will eventually develop steroid-resistant or steroid-refractory GVHD (SR-GVHD), which has an extremely poor prognosis. Many novel strategies that showed promising response rates in early phase I/II trials for the prevention and treatment of acute GVHD exhibited disappointing effects on patient survival in the SR-GVHD setting. The discovery of novel treatments has been further complicated by the absence of a clinically-relevant animal model. Nevertheless, the combined knowledge from translational studies using bone marrow transplantation models and clinical trials including SR-GVHD patients has begun to reveal novel mechanisms for inhibiting T cell signaling and promoting tissue regeneration, which has contributed to a better understanding of the SR-GVHD pathophysiology. Herein, we discuss recently elucidated cellular and molecular mechanisms that may provide the rational for novel biologically-driven treatments for SR-GVHD.